tirzepatide day 1 🥳 Here's to day 1! :

You can take it at any time of day

This article reviews the evidence, safety considerations, and why personalized GLP-1 protocols informed by genetic factors may offer safer, more

Tiny study

Efficacy and safety data were sourced from the STEP trials (Body Mass Index, systolic blood pressure and glycemic status) from a cohort of adults aged on average 48 years with obesity (BMI30 kg/m2) and 1 obesity-related comorbidities, over a time horizon of 40 years

Safe, simple instructions from a Jersey Village weight loss clinic.

From a mechanistic perspective, the findings reinforce the concept that GLP-1 receptor agonists exert cardiovascular benefit beyond glucose lowering, likely through integrated effects on endothelial function, inflammation, and metabolic regulation